{"id":691155,"date":"2022-10-03T08:16:14","date_gmt":"2022-10-03T12:16:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/"},"modified":"2022-10-03T08:16:14","modified_gmt":"2022-10-03T12:16:14","slug":"enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/","title":{"rendered":"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit"},"content":{"rendered":"
\n

\n Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) — <\/strong> Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th<\/sup> Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022.<\/p>\n

Enlivex\u2019s presentation will take place at 2:30 PM ET on October 06, 2022. During the presentation, company management will provide an overview of Enlviex’s clinical programs in sepsis and solid cancers, and review previously presented data supporting these programs. Those interested in registering for the summit can do so here<\/a>.<\/p>\n

\n ABOUT THE <\/strong>
\n 4<\/strong>
\n
\n th<\/strong>
\n <\/sup>
\n MACROPHAGE-<\/strong>
\n D<\/strong>
\n IRECTED THERAPIES SUMMIT<\/strong>\n <\/p>\n

The 4th Macrophage-directed Therapies Summit will include presentations regarding approaches to target \u201cdon\u2019t eat me signal\u201d, strategies to reprogram tumor-associated macrophages, and techniques to discover next-generation targeting methods to develop highly effective and controlled therapies. The program will delve into clinical translatability, novel targets beyond CD47, combination strategies vs. monotherapy approaches, and lean on the lessons learned in oncology to bridge the gap between diseases in autoimmunity, inflammation, and regenerative medicine.<\/p>\n

\n ABOUT ENLIVEX<\/strong>\n <\/p>\n

Enlivex is a clinical stage immunotherapy company developing Allocetra\u2122, a universal, off-the-shelf cell therapy designed to\u00a0reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit\u00a0http:\/\/www.enlivex.com.<\/u><\/a><\/p>\n

Safe Harbor Statement:\u00a0 This press release contains forward-looking statements, which may be identified by words such as \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cshould,\u201d \u201cwould\u201d, \u201ccould,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201csuggests,\u201d \u201chas the potential to\u201d and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA<\/em>TM<\/em><\/sup>\u00a0programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.\u00a0 Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex\u2019s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and\/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<\/em>TM<\/em><\/sup>\u00a0product line could also be affected by <\/em>a number of<\/em> other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.\u00a0 In addition to the risk factors described above, investors should consider the economic, competitive, governmental, <\/em>technological<\/em> and other factors discussed in Enlivex\u2019s <\/em>filings with the Securities and Exchange Commission, including in the Company\u2019s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.\u00a0 The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.<\/em><\/p>\n

\n ENLIVEX CONTACT<\/strong>
\n
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com<\/u><\/a><\/p>\n

\n INVESTOR RELATIONS CONTACT<\/strong>
\n
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com<\/u><\/a><\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022. Enlivex\u2019s presentation will take place at 2:30 PM ET on October 06, 2022. During the presentation, company management will provide an overview of Enlviex’s clinical programs in sepsis and solid cancers, and review previously presented data supporting these programs. Those interested in registering for the summit can do so here. ABOUT THE 4 th MACROPHAGE- D IRECTED THERAPIES SUMMIT The 4th Macrophage-directed Therapies Summit will include presentations regarding approaches to target \u201cdon\u2019t … <\/p>\n

Continue reading “Enlivex to Present at the 4th Macrophage-Directed Therapies Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-691155","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnlivex to Present at the 4th Macrophage-Directed Therapies Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022. Enlivex\u2019s presentation will take place at 2:30 PM ET on October 06, 2022. During the presentation, company management will provide an overview of Enlviex’s clinical programs in sepsis and solid cancers, and review previously presented data supporting these programs. Those interested in registering for the summit can do so here. ABOUT THE 4 th MACROPHAGE- D IRECTED THERAPIES SUMMIT The 4th Macrophage-directed Therapies Summit will include presentations regarding approaches to target \u201cdon\u2019t … Continue reading "Enlivex to Present at the 4th Macrophage-Directed Therapies Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-03T12:16:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzYwNyM1MTgzNzY1IzUwMDA2NTE3NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit\",\"datePublished\":\"2022-10-03T12:16:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/\"},\"wordCount\":635,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzYwNyM1MTgzNzY1IzUwMDA2NTE3NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/\",\"name\":\"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzYwNyM1MTgzNzY1IzUwMDA2NTE3NA==\",\"datePublished\":\"2022-10-03T12:16:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzYwNyM1MTgzNzY1IzUwMDA2NTE3NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NzYwNyM1MTgzNzY1IzUwMDA2NTE3NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/","og_locale":"en_US","og_type":"article","og_title":"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit - Market Newsdesk","og_description":"Nes-Ziona, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will participate in, and present at, the 4th Macrophage-directed Therapies Summit, which is taking place in Boston, Massachusetts from October 4-6, 2022. Enlivex\u2019s presentation will take place at 2:30 PM ET on October 06, 2022. During the presentation, company management will provide an overview of Enlviex’s clinical programs in sepsis and solid cancers, and review previously presented data supporting these programs. Those interested in registering for the summit can do so here. ABOUT THE 4 th MACROPHAGE- D IRECTED THERAPIES SUMMIT The 4th Macrophage-directed Therapies Summit will include presentations regarding approaches to target \u201cdon\u2019t … Continue reading \"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-03T12:16:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzYwNyM1MTgzNzY1IzUwMDA2NTE3NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit","datePublished":"2022-10-03T12:16:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/"},"wordCount":635,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzYwNyM1MTgzNzY1IzUwMDA2NTE3NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/","name":"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzYwNyM1MTgzNzY1IzUwMDA2NTE3NA==","datePublished":"2022-10-03T12:16:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzYwNyM1MTgzNzY1IzUwMDA2NTE3NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NzYwNyM1MTgzNzY1IzUwMDA2NTE3NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-to-present-at-the-4th-macrophage-directed-therapies-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enlivex to Present at the 4th Macrophage-Directed Therapies Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691155","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=691155"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/691155\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=691155"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=691155"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=691155"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}